Progesterone Receptor Negative Withdrawn Phase 1 / 2 Trials for Glembatumumab vedotin (DB05996)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03326258Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryTreatment